Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Agenus ( (AGEN) ) has provided an announcement.
On June 3, 2025, Agenus and Zydus Pharmaceuticals (USA) Inc. entered into agreements for Zydus to acquire Agenus’s manufacturing assets, a minority stake in the company, and commercial rights in India and Sri Lanka for certain intellectual property. The companies submitted a filing to the Committee on Foreign Investment in the United States (CFIUS) for review. On September 17, 2025, CFIUS requested a full notice application, delaying the anticipated closing of these transactions to the fourth quarter of 2025.
The most recent analyst rating on (AGEN) stock is a Sell with a $4.50 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.
Spark’s Take on AGEN Stock
According to Spark, TipRanks’ AI Analyst, AGEN is a Underperform.
Agenus’s overall stock score is primarily impacted by its challenging financial performance, marked by negative profitability and cash flow issues. Technical analysis suggests mixed signals with some long-term support but short-term bearish momentum. The valuation is weak due to negative earnings and lack of dividend yield, further weighing down the score.
To see Spark’s full report on AGEN stock, click here.
More about Agenus
Average Trading Volume: 838,416
Technical Sentiment Signal: Sell
Current Market Cap: $146.6M
Find detailed analytics on AGEN stock on TipRanks’ Stock Analysis page.